A PHASE II STUDY OF DEPSIPEPTIDE IN PTS W/ RELAPSED/REFRACTORY MULTI MYELOMA

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是测试抑郁肽作为治疗复发/复发性多发性骨髓瘤患者的安全性和有效性。如果患者同意，我们还将测试患者骨髓样本，以测试哪些基因（如果有的话）会受到抑郁肽的影响。在第1、8和15天，通过外周静脉或中央静脉导管，以13mg/m2的剂量持续4小时给药。周期将每28天重复一次，直到疾病进展，患者出现无法忍受的副作用，或撤回同意。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to test the safety and effectiveness of Depsipeptide as a treatment for patients with relapsed/refratory mutliple myeloma. If patients agree, we will also be testing samples of patients' bone marrow to test which genes, if any, will be affected by depsipeptide. Depsipeptide will be administered at 13mg/m2 over 4 hours on days 1, 8, and 15 through a peripheral IV or central line. Cycles will be repeated every 28 days until disease progression, patient experiences intolerable side effects, or withdraws consent.